ANI Pharmaceuticals, Inc. (ANIP)

Market Cap	1.45B
Revenue (ttm)	614.38M
Net Income (ttm)	-20.15M
Shares Out	20.31M
EPS (ttm)	-1.04
PE Ratio	n/a
Forward PE	11.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	470,377
Open	70.71
Previous Close	70.82
Day's Range	69.87 - 71.79
52-Week Range	52.50 - 73.72
Beta	0.56
Analysts	Strong Buy
Price Target	80.13 (+12.02%)
Earnings Date	May 9, 2025

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group pu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 897
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIP
• Website: https://www.anipharmaceuticals.com

Analyst Forecast

According to 8 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price forecast is $80.13, which is an increase of 12.02% from the latest price.

Price Target

$80.13

(12.02% upside)

Analyst Consensus: Strong Buy